tbuckley/cabot-search huggingface dataset:
FUNCTIONAL OUTCOMES OF CARDIAC REHABILITATION: WEIGHING IN THE OBESITY PARADOX
Authors: Sameer Raina, Sirish Shrestha, Paurush Ambesh, Kaley Garloch, Ashwin Bhirud, Sujal Modi, Amy Edmond, Mohamad Alkhouli, Vinay Badhwar, Partho Sengupta
Journal: Journal of the American College of Cardiology (2019)
Abstract 277: Enhanced Mitochondrial Calcium Uptake Promotes Deleterious Remodeling and Impaired Left Ventricular Function During Chronic Adrenergic Stimulation
Authors: Joanne F Garbincius, Timothy S Luongo, Jonathan P Lambert, John W Elrod
Journal: Circulation Research (2018)

The mitochondrial calcium uniporter (MCU) constitutes the pore-forming unit of the mitochondrial calcium uniporter channel (mtCU) and is necessary for mitochondrial Ca 2+ ( m Ca 2+ ) uptake. We previously reported that MCU is required to increase cardiac energetics and contractility in response to acute β-adrenergic stimulation. However, deletion of MCU has no detrimental effect on basal cardiac function or metabolism. While these findings support a role for MCU-dependent Ca 2+ flux in functional adaptations to acute stress, little is known about the involvement of MCU in cardiac responses to sustained stress. We compared mice with adult, cardiomyocyte (ACM)-specific loss ( Mcu fl/fl ; Mcu -cKO) or gain (CAG-CAG-MCU; MCU-Tg) of MCU function to explore the role of m Ca 2+ uptake in a model of chronic catecholamine overload. Biophysical characterization confirmed that MCU overexpression enhanced and MCU deletion inhibited ACM m Ca 2+ uptake. Neither loss nor gain of MCU had a significant impact on baseline contractile function. In αMHC-MCM control mice, fractional shortening was transiently increased after 2 days of isoproterenol infusion (Fig 1). This early increase in contractility was attenuated in Mcu -cKO mice. MCU-Tg mice exhibited decreased fractional shortening at 7 and 14 days of isoproterenol infusion. This detrimental effect on LV function was associated with increased LV dilation, HW/BW ratio, and lung edema as compared to αMHC-MCM controls. These data suggest that although mtCU-dependent m Ca 2+ uptake is essential for early energetic adaptations to high adrenergic load, under conditions of chronic adrenergic stress it is maladaptive and predisposes to heart failure.
Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis
Authors: Torben Mentrup, Kosta Theodorou, Florencia Cabrera-Cabrera, Andreas O. Helbig, Kathrin Happ, Marion Gijbels, Ann-Christine Gradtke, Björn Rabe, Akio Fukumori, Harald Steiner, Andreas Tholey, Regina Fluhrer, Marjo Donners, Bernd Schröder
Journal: The Journal of Experimental Medicine (2019)

The lectin-like oxidized LDL receptor 1 (LOX-1) is a key player in the development of atherosclerosis. LOX-1 promotes endothelial activation and dysfunction by mediating uptake of oxidized LDL and inducing pro-atherogenic signaling. However, little is known about modulators of LOX-1–mediated responses. Here, we show that the function of LOX-1 is controlled proteolytically. Ectodomain shedding by the metalloprotease ADAM10 and lysosomal degradation generate membrane-bound N-terminal fragments (NTFs), which we identified as novel substrates of the intramembrane proteases signal peptide peptidase–like 2a and b (SPPL2a/b). SPPL2a/b control cellular LOX-1 NTF levels which, following self-association via their transmembrane domain, can activate MAP kinases in a ligand-independent manner. This leads to an up-regulation of several pro-atherogenic and pro-fibrotic targets including ICAM-1 and the connective tissue growth factor CTGF. Consequently, SPPL2a/b-deficient mice, which accumulate LOX-1 NTFs, develop larger and more advanced atherosclerotic plaques than controls. This identifies intramembrane proteolysis by SPPL2a/b as a novel atheroprotective mechanism via negative regulation of LOX-1 signaling.
ASSOCIATION BETWEEN PLAQUE TYPES, SYSTEMATIC INFLAMMATION, AND LIPID-LOWERING EFFECT OF STATIN IN ACUTE MYOCARDIAL INFARCTION PATIENTS
Authors: Runzhen Chen, Peng Zhou, Chen Liu, Yu Tan, Sheng Zhaoxue, Jiannan Li, Jinying Zhou, Hanjun Zhao, Song Li, Hongbing Yan
Journal: Journal of the American College of Cardiology (2019)
INFLUENCE OF PLATELET REACTIVITY AND FIBRINOGEN LEVELS ON CLINICAL OUTCOMES IN EAST ASIAN PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION
Authors: Min Gyu Kang, Jong-Hwa Ahn, Kyehwan Kim, Jae Seok Bae, Jeong Yoon Jang, Hyun Woong Park, Jin-Sin Koh, Jeong Rang Park, Yongwhi Park, Seok Jae Hwang, Kwak Choong Hwan, Jinyong Hwang, Young-Hoon Jeong
Journal: Journal of the American College of Cardiology (2019)
IMPACT OF LEFT VENTRICULAR END-SYSTOLIC VOLUME ON THE EFFECTIVENESS OF CARDIAC RESYNCHRONIZATION THERAPY: A MADIT-CRT LONG-TERM SUB-STUDY
Authors: Krishna Rao, Nikhila S. Rao, Nilesh S. Rao, Scott McNitt, Bronislava Polonsky, Ilan Goldenberg, Scott Solomon, Valentina Kutyifa
Journal: Journal of the American College of Cardiology (2019)
Abstract 267: Safety and Efficacy of a Combinatorial CCN5/SERCA2a Gene Delivery Approach for Arrhythmia Suppression in a Chronic Model of Angiotensin II (ANG) Induced Cardiac Hypertrophy and Failure
Authors: Nour Raad, Dongtak Jeong, Woo Jin Park, Fadi Akar
Journal: Circulation Research (2018)

Background: Structural &amp; electromechanical remodeling promotes the incidence of ventricular tachycardia (VT) during progression from compensated hypertrophy to heart failure. The multifactorial nature of VT during disease progression presents a major challenge for conventional anti-arrhythmic approaches. Objective: To determine the safety &amp; efficacy of the antifibrotic matricellular protein CCN5 and a novel combinatorial vector carrying CCN5 and SERCA2a (CCN5/S2a) for prevention of VT. Methods: Adult mice (N=15) underwent chronic ANG infusion (3mg/kg/d) for 2 wk. Mice were subsequently randomized for treatment with AAV9 vectors carrying CCN5, CCN5/S2a, or an empty vector and were maintained for another 2 wk. Age matched mice served as controls (Ctrl). Cardiac function was serially assessed by echocardiography. Optical mapping was performed in perfused hearts before &amp; after challenge with isoproterenol and rapid pacing. VT threshold (VT-t) was defined as the pacing frequency required for induction of sustained VT. Results: ANG infusion resulted in a biphasic change in fractional shortening (FS) consistent with an early phase of compensated hypertrophy followed by decompensation. Late decompensation was associated with adverse electrophysiological (EP) remodeling, including action potential prolongation (21.3±2.4ms in ANG vs 17.5±1.9ms in Ctrl), conduction slowing (0.43±0.04m/s in ANG vs 0.57±0.08m/s in Ctrl) and susceptibility for pacing induced VT (VT-t 21.3±1.2Hz in ANG vs 25.8±1.4Hz in Ctrl). At a cut-off frequency of 22Hz, 5/5 ANG vs 0/7 Ctrl heart were prone to VT. Treatment of ANG mice with CCN5 and the combinatorial CCN5/S2a vector suppressed VT susceptibility by increasing VT-t (25.9±2.9Hz for CCN5, 28.4±2.6Hz for CCN5/S2a). Mechanistically, CCN5/S2a delivery reversed EP and structural remodeling, which in turn prevented the formation of the critical lines of block that maintained VT circuits. In addition, CCN5/S2a fully abrogated the late decrease in FS. Conclusion: Delivery of a combinatorial AAV9 vector carrying CCN5/S2a during the early phase of compensated hypertrophy prevents the progression of electrical and structural remodeling, thereby suppressing the incidence of VT while preserving mechanical function.
Abstract P3-16-01: Responding at patient's time of need: Scaling rapid access to evidence-based treatment plans
Authors: N Ramarajan, R Srivastava, F Begum, S Gupta, C Pramesh, R Badwe
Journal: Cancer Research (2019)

Abstract Background: Cancer patients worldwide feel intense anxiety, often racing to start treatments at non expert centers. Further, imbalanced oncologist to patient ratios (˜1600: 1.8 M in India, ˜23,000: 15M in USA), impedes access to expertise. We study the impact of rapid evidence based expert treatment plans in relieving patient anxiety. Navya, a health services technology, generates personalized treatment plans that maps within NCCN Resource Stratified Guidelines [SABCS 2017]. This is vetted on mobile by oncologists at tertiary centers like TMC NCG to provide expert opinion reports to patients. Since 2015, ˜19,457 patients from 57 countries have reached out for an online opinion. On the ground, 78% of patients received evidence based treatments recommended by Navya [ASCO 2017]. Methods: To assess impact of timeliness, a prospective series of patients (from Sep '17 to April '18) were asked: “Were you relieved to receive expert opinion report in [x] days?” “Does it matter to you to receive expert opinion report in 1 day?” To assess time savings, preliminary reports with treatment options from NCCN and TMC NCG guidelines were shared with patients who matched all guidelines criteria. Subsequently, expert opinion reports were shared as usual. Results: 543/701 patients responded to phone follow-up. 97% [± 3.2] were relieved to receive expert opinion reports in 1-2 days (103/106) vs 83% [± 3.8 ] for 3+ days (365/437). Of those not relieved by 3+ day turnaround, 83% stated that it would matter to receive expert opinion reports in 1 day (60/72). The first 300 preliminary reports shared in median time of 3.37 hours, resulted in 90% time savings vs expert opinion reports. On 10% of the preliminary reports, experts added information such as de-/escalating therapy (18/31), and additional diagnostic tests (6/31). Conclusions: Navya relieves patient anxieties by responding at the time of need with evidence based treatment plans. Scaling such health services technologies to patients worldwide is feasible. Citation Format: Ramarajan N, Srivastava R, Begum F, Gupta S, Pramesh C, Badwe R. Responding at patient's time of need: Scaling rapid access to evidence-based treatment plans [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-16-01.
Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATETM and RESONATE-2TM with the French Lyon-Sud Database
Authors: Gilles A. Salles, Lucile Baseggio, Emmanuel Bachy, Clementine Sarkozy, Herve Ghesquieres, Joris Diels, Hervé Besson, Finlay MacDougall, Ruben Hermans, Nollaig Healy, Jamie Garside, Wafae Iraqi, Evelyne Callet-Bauchu
Journal: Blood (2016)
ATRIAL FIBRILLATION WELLNESS PROGRAM LEADS TO DECREASED EMERGENCY ROOM VISITS AND 30 DAY RE-HOSPITALIZATION RATES
Authors: Nitesh Sood, Katie Calheta, Rose Larrivee, Ramin Davoudi, Arnoldas Giedrimas, Peter Cohn, David Teixeira, Kelly Walker, Brianne Cabral, Lori Mullins, Debra Benevides
Journal: Journal of the American College of Cardiology (2019)
Abstract 447: The Role of Extracellular cAMP in the Pathogenesis of Pulmonary Arterial Hypertension
Authors: Yassine Sassi, Carlos bueno-Beti, Carly Jones, Guillaume Bonnet, Lahouaria Hadri, Roger J Hajjar
Journal: Circulation Research (2018)

Pulmonary arterial hypertension (PAH) is an uncommon, progressive, life-threatening and often fatal disease. Despite advances in PAH therapy, there is no cure for PAH, and new therapies need to be developed. Activation of G-protein-coupled receptors stimulates adenylyl cyclase, leading in vascular smooth muscle cells to an increase in intracellular cyclic adenosine monophosphate (cAMP) formation and reduced cell proliferation in vitro and in vivo . Yet, the last two decades of research have shown that there is more to the role of cAMP than ever expected from this molecule. Stimulated cells transport cAMP outside the cells, a process that is mediated by the multidrug resistance-associated proteins (MRPs). Herein, we investigated the role of extracellular cAMP in the lung and asked whether it may act on pulmonary vascular remodeling. By employing a fluorescence resonance energy transfer (FRET)-based sensor, we found that extracellular cAMP activates intracellular cAMP formation in human pulmonary artery smooth muscle cells (hPASMC) and endothelial cells (hPAEC). Extracellular cAMP, via binding of its metabolite adenosine to the type A2 receptor, reduced hPASMC and hPAEC proliferation and migration by controlling the PKA/CREB pathway. To test for a role of extracellular cAMP in the pulmonary vasculature, we used rat-monocrotaline and mouse-hypoxia as in vivo models of PAH. Rats treated with monocrotaline developed PAH with increased pulmonary artery pressures (PAP) and right ventricular (RV) hypertrophy. Extracellular cAMP infusion significantly prevented and reversed these structural changes. Extracellular-cAMP-treated rats displayed lower RV systolic pressure and Fulton index, as well as decreased PAP. In line with these observations, we found infused cAMP to potently repress RV hypertrophy, RV systolic pressure, perivascular lung fibrosis and pulmonary arteries remodeling in mice exposed to Sugen5416 and chronic hypoxia. Together, our results assign extracellular cAMP a potent regulatory role in pulmonary vascular cells, and suggest targeting the extracellular cAMP signaling pathway to limit pulmonary vascular remodeling and PAH.
TRENDS AND FACTORS ASSOCIATED WITH USE OF MULTIPLE ARTERIAL GRAFTS FOR MULTIVESSEL CORONARY ARTERY BYPASS GRAFT SURGERY: A STATE-WIDE ANALYSIS OF 68,357 PROCEDURES
Authors: Gennaro Giustino, Doaa Alsaleh, Mario Gaudino, Natalia Egorova, Faisal Bakaeen, A. Gillinov, Alan Moskowitz, Pierre Voisine, John Puskas, John Alexander, Peter Smith, Annetine Gelijns, Stephen Fremes
Journal: Journal of the American College of Cardiology (2019)
BASELINE GLOBAL LONGITUDINAL STRAIN IS ASSOCIATED WITH ALL-CAUSE MORTALITY IN PATIENTS TREATED WITH TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Miho Fukui, Michael S. Sharbaugh, Floyd Thoma, Ibrahim Sultan, Suresh Mulukutla, Hesham Elzomor, Joon Lee, John Schindler, Thomas Gleason, Joao L. Cavalcante
Journal: Journal of the American College of Cardiology (2019)
Medical students need better training on the needs of LGBT+ patients
Authors: Jeremias L K Reich, Kanay Khakhria
Journal: BMJ (2019)

Salkind and colleagues discuss the very real consequences of underserving LGBT+ patients and say that pragmatic approaches may better meet the needs of this population.1 But education about inclusion needs to start at medical school to incorporate inclusive thinking from the beginning of shaping new doctors. This is almost entirely missing in today’s medical school curriculum.

The most recent Stonewall …
NON-CONTRAST CARDIAC MAGNETIC RESONANCE BASED DETECTION OF MYOCARDIAL DAMAGE USING MYOCARDIAL STRAIN ANALYSIS
Authors: Jennifer Erley, Natalie Tapaskar, Nazia Alvi, Nina Rashedi, Davide Genovese, Stephanie A. Besser, Sebastian Kelle, Keigo Kawaji, Neha Goyal, Roberto Lang, Victor Mor-Avi, Amit Patel
Journal: Journal of the American College of Cardiology (2019)
Prescription Drugs—List Price, Net Price, and the Rebate Caught in the Middle
Authors: Stacie B. Dusetzina, Peter B. Bach
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PREDICTORS OF LOW CARDIAC INDEX IN SUBMASSIVE PULMONARY EMBOLISM
Authors: Kateria Porcaro, Jeremiah Haines, Stephen Morris, Demetrios Doukas, Erin Mancl, Dalila Masic, Estefania Oliveros, Vladimir Lakhter, Carlos Bechara, John J. Lopez, Verghese Mathew, Jawed Fareed, Amir Darki, Yevgeniy Brailovsky
Journal: Journal of the American College of Cardiology (2019)
Outcomes in Chronic Hemodynamically Significant Aortic Regurgitation and Limitations of Current Guidelines
Authors: Li-Tan Yang, Hector I. Michelena, Christopher G. Scott, Maurice Enriquez-Sarano, Sorin V. Pislaru, Hartzell V. Schaff, Patricia A. Pellikka
Journal: Journal of the American College of Cardiology (2019)
EVALUATION OF NON-CULPRIT LESIONS IN ACUTE CORONARY SYNDROMES USING QUANTITATIVE FLOW RATIO
Authors: Masao Yamaguchi, Masahiro Hoshino, Tomoki Horie, Haruhito Yuki, Yoshinori Kanno, Hidenori Hirano, Yohei Sumino, Hiroaki Ohya, Masahiro Hada, Yoshihisa Kanaji, Akinori Sugano, Taishi Yonetsu, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2019)
COMPARISON OF UNITED STATES AND EUROPEAN CRITERIA FOR HYPERTENSION IN A LARGE COHORT OF COMPETITIVE ATHLETES EXAMINED AS PART OF PRE-PARTICIPATION EVALUATION
Authors: Kristofer Hedman, Kegan Moneghetti, Jeff W. Christle, Shadi P. Bagherzadeh, Francois Haddad, Euan A. Ashley, Victor Froelicher
Journal: Journal of the American College of Cardiology (2019)
Abstract 18679: Cyclin-D2 Overexpression Enhances the Regenerative Potency of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes
Authors: Wuqiang Zhu, Meng Zhao, Saidulu Mattapally, Jianyi Zhang
Journal: Circulation (2017)

Introduction: The effectiveness of transplanted human induced pluripotent, stem cell-derived cardiomyocytes (hiPSC-CMs) for treatment of ischemic myocardial injury is limited by the exceptionally low engraftment rate. Objective: To determine whether overexpression of the cell cycle activator cyclin D2 (CD2) in hiPSC-CMs can increase the graft size and improve myocardial recovery in a mouse model of myocardial infarction (MI) by increasing the proliferation of grafted cells. Methods and Results: Human cyclin D2 was delivered to hiPSCs via lenti-viral mediated gene transfection. In cultured cells, markers for cell cycle activation and proliferation were ~3-7 folds higher in CD2-overexpressing hiPSC-CMs (hiPSC-CD2OECMs) than in hiPSC-CMs with normal levels of CD2 (hiPSC-CD2WTCMs) (p<0.01). The pluripotent genes (Oct 4, Sox2, Nanog) decrease to minimal- and undetectable-levels at Day 1 and 10 after differentiate to CMs. In the mouse MI model, cardiac function, infarct size, and the number of engrafted cells w...
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor–Positive Breast Cancer
Authors: Joshua Z. Drago, Sarat Chandarlapaty, Komal Jhaveri
Journal: Cancer Discovery (2019)

Abstract Summary: Standard treatment for estrogen receptor–positive metastatic breast cancer involves antiestrogen therapy used alone or in combination with inhibitors of CDK4/6 or mTOR; this approach works mechanistically by eliciting and reinforcing cell-cycle arrest. In this issue, Lok and colleagues diverge from this paradigm by combining the BCL2 inhibitor venetoclax with tamoxifen in a phase Ib clinical trial, building on preclinical work to demonstrate that targeting apoptosis could represent a promising new strategy in the treatment of breast cancer. See related article by Lok et al., p. 354.
Abstract OT2-05-02: International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1)
Authors: S Imoto, M Futamura, M Toi, Y Fujiwara, T Ueno, Y-H Im, S-A Im, SG Ahn, JE Lee, YH Park, K Wang, Y Kitagawa, M Nishiyama
Journal: Cancer Research (2019)

Abstract Breast cancer (BC) is so-called “systemic disease”, because disseminated cancer cells in bone marrow and blood are detected even in early BC patients. Despite adjuvant therapy and postoperative radiation therapy, patients with triple negative BC and Luminal B-like BC often relapse early and systemic therapy is the only way to control disease progression. On the other hand, some BC patients relapse several years later. In such patients, oligometastases are occasionally diagnosed, because metastatic cancer cells are slowly growing and indolent. Oligometastatic BC is defined as low volume metastatic disease with limited number and size of metastatic lesions (up to five and not necessarily in the same organ). This definition is proposed in the Advanced Breast Cancer guidelines that are developed as a joint effort from European School of Oncology and European Society of Medical Oncology. Several retrospective studies demonstrated survival benefit of locoregional therapy in addition to systemic therapy. Locoregional therapy consisted of surgical resection, radiation therapy, ablation therapy, etc. However, it remains unclear about survival benefit of combined therapy in oligometastatic BC. To improve the standard of cancer treatment through the cooperate studies on more effective therapeutic strategies based on drugs, surgery and/or radiotherapy, Federation of Asian Clinical Oncology (FACO) was established in 2012 by Chinese Society of Clinical Oncology (CSCO), Korean Society of Medical Oncology (KSMO) and Japan Society of Clinical Oncology (JSCO). Thus, FACO conducted a retrospective cohort study on oligometastatic BC. The primary endpoint is to compare the estimated 5-year overall survival (OS) of oligometastatic BC patients treated with combined therapy and systemic therapy alone. To hypothesize that combined therapy has more advantage of OS in oligometastatic BC, the 5-year OS rates are expected to be 50% and 40%, respectively. The estimated sample size is calculated to be the number of 698 cases (349 cases in each group) needed to prove the superiority of survival with a two-sided type I error rate of 5% and a statistical power of 80%. Case registry opened in February 2018 and will close in January 2019. We planned to register 700 cases, i.e., 234 cases each from investigators of CSCO, KSMO and JSCO. Update information will be discussed. Citation Format: Imoto S, Futamura M, Toi M, Fujiwara Y, Ueno T, Im Y-H, Im S-A, Ahn SG, Lee JE, Park YH, Wang K, Kitagawa Y, Nishiyama M. International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-05-02.
IMPAIRED BIOENERGETICS IN RIGHT VENTRICULAR FAILURE IS ASSOCIATED WITH LIPID PEROXIDATION AND DECREASED MITOCHONDRIAL DYNAMICS
Authors: Hyun Tae Hwang, Nefthi Sandeep, Ming Ming Zhao, Dong-Qing Hu, Ingrid Lan, Michael Coronado, Kristina Kooiker, Giovanni Fajardo, Daniel Bernstein, Sushma Reddy
Journal: Journal of the American College of Cardiology (2019)
PACEMAKER FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT ASSOCIATED WITH INCREASED TRICUSPID REGURGITATION
Authors: Paul Nona, Sachin Parikh, Bryan Zweig, Marvin Eng, James Lee, Tiberio Frisoli, Tongwa Aka, Michael M. Isley, William O'Neill, Dee Dee Wang
Journal: Journal of the American College of Cardiology (2019)
CURRENT DIASTOLIC GUIDELINES UNDERESTIMATE THE PREVALENCE OF DIASTOLIC DYSFUNCTION IN CIRRHOTIC PATIENTS
Authors: James MacNamara, Ross Deppe, Youssef Garcia-Bengochea, Pranay Prabhakar, Kara Raphael, Robin Porter, Anjali Parekh, Anjana Pillai, Maan Jokhadar, Satyam Sarma
Journal: Journal of the American College of Cardiology (2019)